About
DevaCell Inc develops synthetic vector-based immunotherapies using their ONCoat™ platform, including oncolytic virus therapies, vaccines, and gene therapies designed to selectively attack tumor cells and activate the patient's immune system.
Explore DevaCell Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.